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Abstract. Many ErbB2-positive cancers may show intrinsic
resistance, and the frequent development of acquired resistance
to ErbB-targeted agents represents a substantial clinical
problem. The constitutive NF-κB activation in some HER-2/
neu positive breast cancer may represent a potential cause of
resistance to trastuzumab therapy. Preclinical data revealed
that 4-(N-Methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone
(NNK), the tobacco-specific nitrosamine is able to enhance
NF-κB DNA binding activity and theoretically to increase
the resistance to trastuzumab. Two hundred and forty-eight
women with pathologically confirmed, uni- or bidimen-
sionally measurable, HER-2-positive metastatic breast cancer
(MBC) treated with trastuzumab-based therapy as first line
combination for metastatic disease were considered eligible.
For all included patients data on smoking habit were
detectable from medical records. We retrospectively analysed
the smoking habits of 248 MBC patients and correlated these
habits with activity and efficacy of trastuzumab-based therapy.
No statistically significant difference in terms of response
rate (RR), time to progression (TTP) and overall survival
(OS) was identified between smokers (former plus active
smokers) and never smokers. Moreover, no statistically
significant difference in terms of RR, TTP and OS was
identified either comparing active smokers and former
smokers. Moreover, we did not observed any significant
statistical difference in terms of TTP and OS between
smokers ≥10 cigarettes/day and <10 cigarettes/day. This
study clearly showed lack of any correlation between
cigarette smoking habit and both activity and efficacy of
trastuzumab-based first line therapy in metastatic HER2/neu
positive breast cancer patients.
Introduction
There are four members of the EGFR family of receptors,
each of which is capable of forming heterodimers with other
family members. These members are EGFR (erbB1, HER1),
HER2 (erbB2/neu), erbB3 (HER3), and erbB4 (HER4). 
The discovery that some women with early-stage breast
cancer overexpress HER2 has led to the development of the
recombinant humanized monoclonal antibody trastuzumab
(Herceptin®; Genentech, San Francisco, CA). Trastuzumab is
actually indicated for patients with tumors that overexpress
HER2 and has an excellent therapeutic index, with consistent
evidence that it improves the efficacy of available therapies
in all stages of breast cancer, both in adjuvant and in metastatic
settings (1,2). 
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However, many ErbB2-positive cancers may show intrinsic
resistance, and the frequent development of acquired resistance
to ErbB-targeted agents represents a substantial clinical
problem. There are many potential mechanisms for resistance
to this type of therapy, including the formation of alternative
ErbB signaling complexes and crosstalk with other pathways
(3). 
Nuclear factor-κB (NF-κB), a transcription factor with
pleotropic effects, is a downstream mediator of growth
signaling in erbB2 (HER-2/neu) receptor-positive cancer and
activation of NF-κB in human breast cancer is confined pre-
dominately to those that express members of the EGF family
of receptors, including the EGF receptor (erbB1) and erbB2 (4).
The constitutive NF-κB activation in some HER-2/neu positive
breast cancer may represent a potential cause of resistance
to trastuzumab therapy (5). Infact, preliminary results also
revealed that specific inhibitors of NF-κB and the EGFR
family of cell surface receptors in combinations have
demonstrated to block proliferation synergistically at
concentrations which are ineffective when used individually
(6). Preclinical data revealed that 4-(N-Methyl-N-nitrosamino)-
1-(3-pyridyl)-1-butanone (NNK), the tobacco-specific
nitrosamine, was able to stimulate the proliferation of
SW1116 colon cancer cell line enhancing NF-κB DNA
binding activity (7). Moreover, nicotine, the major alcaloid in
tobacco, increases the oxidative stress of colon cancer cells,
leading to the activation of NF-κB, a redox-sensitive
trascription factor (8) and promotes colon cancer cell
proliferation and tumor growth in a dose-dependent manner,
increasing EGFR phosphorylation levels (9). 
Drawing from the above considerations, our group has
evaluated the impact of cigarettes smoking on trastuzumab
efficacy in a large cohort of metastatic breast cancer patients
treated with trastuzumab-based regimens as first line of
therapy.
Materials and methods
Women with pathologically confirmed, uni- or bidimensionally
measurable, HER-2-positive metastatic breast cancer (MBC)
not treated with any drug for metastatic disease were
considered eligible. Patients were required to be ≥18 years
of age, have an Eastern Cooperative Oncology Group perfor-
mance status of 0-2. Patients with samples scoring 3+ by
IHC or positive by FISH were eligible, whereas those with
a 2+ IHC score also had to have a positive result by FISH.
Patients who had received prior chemotherapy for MBC were
excluded although prior adjuvant or neoadjuvant chemo-
therapy was permitted. Concurrent chemotherapy or
hormonal therapy was allowed. Patients with brain metastasis
not responding to treatment were excluded. At least 4 weeks
were required to elapse between last surgery or radiation
therapy with full recovery, and indicator lesions had to be
outside prior radiation fields. 
We considered all consecutive patients for whom data on
smoking habit were detectable from medical records between
2004 and 2007 in the following hospitals: Campus Bio-
Medico University of Rome; Azienda Ospedaliera Univer-
sitaria San Luigi di Orbassano; S. Giovanni di Dio Hospital
of Frattamaggiore; Center for Experimental Research and
Medical Studies San Giovanni Battista, Turin; Section of
Medical Oncology, Università di Palermo; Polo Oncologico
Alessandria-Asti; Unità Funzionale di Oncologia, INI,
Grottaferrata; Medical Oncology, Department of Human
Pathology, University Hospital G. Martino, Messina; Divisione
di Oncologia Medica, Istituto per la Ricerca e la Cura del
Cancro, Candiolo, Torino; and Oncologia Medica, Ospedale
S. Eugenio, Rome. 
Treatment plan. Trastuzumab was administered according to
different schedules (weekly or three-weekly, after induction)
and in association with different cytotoxic agents. Tumor
response was evaluated every 9 weeks using consistent imaging
techniques (CT or MRI). Response assessment was performed
by the investigators according to the Response Evaluation
Criteria in Solid Tumors (RECIST).
Statistical analysis. We conducted the present cohort study to
evaluate whether active or passive cigarettes smoking status
affects time to progression (TTP) and overall survival (OS)
among MBC patients treated with chemotherapy plus
cetuximab. TTP was calculated from the date of starting
trastuzumab-based treatment to the first observation of disease
progression or to death from any cause, occurring within
60 days after the start of treatment or the most recent tumor
assessment. OS time was calculated from the date of starting
trastuzumab-based treatment until death from any cause or
until the date of the last follow-up, at which point data were
censored. The Kaplan-Meier product-limit method was used
for analysis of TTP and OS (10).
Moreover, the differences in terms of TTP and OS between
different groups were evaluated by the log-rank test (11). The
cut-off point for survival data was July 2008; for safety data,
it was March 2007. SPSS software (version 13.05, SPSS,
Chicago, IL) was used for statistical analysis. A P<0.05 was
considered to indicate statistical significance.
Results
We retrospectively analysed the smoking habits of 248 MBC
patients (median age 56 years, range 28-86 years) treated with
different anticancer regimens (paclitaxel- and docetaxel-based:
210 patients; vinorelbine-based: 27 patients; anthracycline-
based; 5 patients; carboplatin-based: 6 patients) plus trastu-
zumab. Table I lists the patient characteristics.
We characterized the following three groups: never
smokers, former smokers (patients who had given up smoking
at least 6 months before the beginning of trastuzumab-based
treatment) and current smokers. Moreover, we further divided
the last group in two sub-populations: patients smoking
≤10, ≥10 cigarettes per day. Data on passive smoking were
collected. A passive smoker was defined as a person who
usually breaths ambient air containing carcinogenic inhalants
from an ‘active’ cigarette smoker at least for 2 h every day
for not less than 10 years. We did not analyse cigar or pipe
smoking. 
As reported in Table I our population was composed of
169 never smokers, 33 former smokers and 46 active smokers,
(20 ≤10 cigarettes/day, 26 >10 cigarettes/day). We included
in this observational trial 59 passive smokers. There were no
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significant differences in terms of age, PS, hormonal receptor
status, grading and trastuzumab-associated chemotherapy
regimen among the three groups determined by their smoking
habit (data not shown). 
No statistically significant difference in terms of response
rate (RR) and TTP has been identified between smokers
(former plus active smokers) and never smokers. The RR
in non-smokers was of 50.6% and in smokers was of 50%
(P=0.736). Fig. 1 shows the median TTP was 15 months
(95% CI: 12.42-17.58) vs. 14.1 (95% CI: 12.62-17.38) in
non-smokers and smokers, respectively (P=0.683). Moreover,
no statistically significant difference in terms of response
rate (RR) and TTP has been identified also comparing
active smokers and former smokers. In particular, the RR in
former smokers was of 52 versus 42.2% in active smokers
(P=0.462). Fig. 2 reports the median TTP was 15 months
(95% CI: 12.54-17.45) vs. 16 (95% CI: 7.46-24.5) in former
smokers and active smokers, respectively (P=0.581). We did
not observe any significant statistical difference in term of
TTP between smokers ≥10 cigarettes/day and <10 cigarettes/
day, with median values of 12 months (95% CI: 6.84-17.15)
and 15 months (95% CI: 11.56-18.43), respectively as
reported in Fig. 3. In the same subgroups we evaluated the
median values of overall survival. Also for overall survival
no significant statistical differences have been observed when
smokers versus non-smokers (P=0.636), active smokers and
former smokers (P=0.431) and smokers of ≥10 cigarettes/day
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Never smokers 169 (68.1%)
Former smokers 33 (13.3%)
Active smokers 46 (18.6%)
–––––––––––––––––––––––––––––––––––––––––––––––––
Figure 1. No statistically significant difference in terms of TTP was
identified between smokers (former plus active smokers) and never smokers
(P=0.683).
Figure 2. No statistically significant difference in terms of TTP was
identified in active or former smokers (P=0.581).
Figure 3. No significant statistical difference was observed in terms of TTP
between smokers of ≥10 cigarettes/day or <10 cigarettes/day.
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and <10 cigarettes/day (P=0.998) were compared (survival
curves not reported). 
Discussion
This study clearly showed lack of any correlation between
cigarette smoking habit and both activity and efficacy of
trastuzumab-based first line therapy in metastatic HER2/
neu-positive breast cancer patients. At the same time these
results deserve to be confirmed prospectively in other
adequately designed clinical trials, given the potentially
relevant implications in the clinical practice. Our results could
be undermined by the use of retrospectively collected
smoking data, rather than data collected at the beginning of
trastuzumab therapy.
It must be considered that smoking habits may change
following a cancer diagnosis as well as during cancer treat-
ment. Moreover, we did not observe any correlation between
cigarette smoking habit and trastuzumab activity and efficacy
considering the entire population. The number of hormonal
receptor positive patients in our cohort was too low in order
to investigate any significant correlation with trastuzumab
activity in this subpopulation. Some additional biases should
be taken in consideration and limit the reproducibility of the
results presented in the present report. Data on smoking habit
in our patients population were, at least partially, obtained
retrospectively, performing a direct question to patients
during a medical visit of by a phone call. This methodology
could led to a selection bias excluding deceased patients
possibly with a worst prognosis. This point could represent
the reason of the longer TTP and OS observed in our analysis
when compared with that observed with the same cancer
population in published clinical trials (9). On the contrary the
observed response rate in the population of smokers vs. non-
smokers is reasonably reliable.
However, despite the constitutive NF-κB activation in
some HER-2/neu positive breast cancer is a frequent genetic
condition (4-7) and it has been demonstrated that nicotine has
a proliferative role on cancer cells through the PI3K/AKT
pathway activation and the PTEN pathway inhibition (8,9),
we may suppose that the potential role of nicotine in inducing
resistance to trastuzumab therapy in MBC is overcome by
other predominant molecular and/or genetic mechanisms
conditioning the proliferation and invasive processes of cancer
in the metastatic phase. With the same rational, the adjuvant
setting of breast cancer appears to represent the best setting
to analyse the potential detrimental effects of nicotine in
trastuzumab based adjuvant therapy. 
In conclusion, despite the potential methodological limits
of the present retrospective study, the large number of included
patients and the very accurate modality of cigarette habit data
collection, allow us to strongly suggest the lack of any activity
and efficacy interaction between smoke and trastuzumab
based therapy in MBC.
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